These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21074975)

  • 1. Ultra high risk (UHR) for psychosis criteria: are there different levels of risk for transition to psychosis?
    Nelson B; Yuen K; Yung AR
    Schizophr Res; 2011 Jan; 125(1):62-8. PubMed ID: 21074975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo.
    McHugh MJ; McGorry PD; Yuen HP; Hickie IB; Thompson A; de Haan L; Mossaheb N; Smesny S; Lin A; Markulev C; Schloegelhofer M; Wood SJ; Nieman D; Hartmann JA; Nordentoft M; Schäfer M; Amminger GP; Yung A; Nelson B
    Schizophr Res; 2018 May; 195():543-548. PubMed ID: 29055567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of clinical distress in young people at ultra high risk of psychosis.
    Rapado-Castro M; McGorry PD; Yung A; Calvo A; Nelson B
    Schizophr Res; 2015 Jun; 165(1):15-21. PubMed ID: 25890793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High remission rates from an initial ultra-high risk state for psychosis.
    Simon AE; Umbricht D
    Schizophr Res; 2010 Feb; 116(2-3):168-72. PubMed ID: 19854621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
    Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
    Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.
    Nelson B; Yuen HP; Wood SJ; Lin A; Spiliotacopoulos D; Bruxner A; Broussard C; Simmons M; Foley DL; Brewer WJ; Francey SM; Amminger GP; Thompson A; McGorry PD; Yung AR
    JAMA Psychiatry; 2013 Aug; 70(8):793-802. PubMed ID: 23739772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State marker properties of niacin skin sensitivity in ultra-high risk groups for psychosis - An optical reflection spectroscopy study.
    Langbein K; Schmidt U; Schack S; Biesel NJ; Rudzok M; Amminger GP; Berger M; Sauer H; Smesny S
    Schizophr Res; 2018 Feb; 192():377-384. PubMed ID: 28602647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis.
    Peralta D; Studerus E; Andreou C; Beck K; Ittig S; Leanza L; Egloff L; Riecher-Rössler A
    Early Interv Psychiatry; 2019 Aug; 13(4):969-976. PubMed ID: 30019850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early psychotic experiences: Interventions, problems and perspectives.
    Dimitrakopoulos S; Kollias C; Stefanis NC; Kontaxakis V
    Psychiatriki; 2015; 26(1):45-54. PubMed ID: 25880383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis.
    Kraan T; van Dam DS; Velthorst E; de Ruigh EL; Nieman DH; Durston S; Schothorst P; van der Gaag M; de Haan L
    Schizophr Res; 2015 Dec; 169(1-3):193-198. PubMed ID: 26585219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents.
    Armando M; Pontillo M; De Crescenzo F; Mazzone L; Monducci E; Lo Cascio N; Santonastaso O; Pucciarini ML; Vicari S; Schimmelmann BG; Schultze-Lutter F
    Schizophr Res; 2015 Dec; 169(1-3):186-192. PubMed ID: 26526751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
    Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
    Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.
    Lo Cascio N; Saba R; Hauser M; Vernal DL; Al-Jadiri A; Borenstein Y; Sheridan EM; Kishimoto T; Armando M; Vicari S; Fiori Nastro P; Girardi P; Gebhardt E; Kane JM; Auther A; Carrión RE; Cornblatt BA; Schimmelmann BG; Schultze-Lutter F; Correll CU
    Eur Child Adolesc Psychiatry; 2016 Oct; 25(10):1091-102. PubMed ID: 26921232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohort.
    Hartmann S; Dwyer D; Cavve B; Byrne EM; Scott I; Gao C; Wannan C; Yuen HP; Hartmann J; Lin A; Wood SJ; Wigman JTW; Middeldorp CM; Thompson A; Amminger P; Schlögelhofer M; Riecher-Rössler A; Chen EYH; Hickie IB; Phillips LJ; Schäfer MR; Mossaheb N; Smesny S; Berger G; de Haan L; Nordentoft M; Verma S; Nieman DH; McGorry PD; Yung AR; Clark SR; Nelson B
    World Psychiatry; 2024 Oct; 23(3):400-410. PubMed ID: 39279417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline grey matter volume of non-transitioned "ultra high risk" for psychosis individuals with and without attenuated psychotic symptoms at long-term follow-up.
    Cropley VL; Lin A; Nelson B; Reniers RLEP; Yung AR; Bartholomeusz CF; Klauser P; Velakoulis D; McGorry P; Wood SJ; Pantelis C
    Schizophr Res; 2016 Jun; 173(3):152-158. PubMed ID: 26032566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of at-risk symptoms for psychosis in children and adolescents.
    Schimmelmann BG; Walger P; Schultze-Lutter F
    Can J Psychiatry; 2013 Jan; 58(1):32-40. PubMed ID: 23327754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification.
    Fusar-Poli P; Cappucciati M; Borgwardt S; Woods SW; Addington J; Nelson B; Nieman DH; Stahl DR; Rutigliano G; Riecher-Rössler A; Simon AE; Mizuno M; Lee TY; Kwon JS; Lam MM; Perez J; Keri S; Amminger P; Metzler S; Kawohl W; Rössler W; Lee J; Labad J; Ziermans T; An SK; Liu CC; Woodberry KA; Braham A; Corcoran C; McGorry P; Yung AR; McGuire PK
    JAMA Psychiatry; 2016 Feb; 73(2):113-20. PubMed ID: 26719911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition and remission in adolescents at ultra-high risk for psychosis.
    Ziermans TB; Schothorst PF; Sprong M; van Engeland H
    Schizophr Res; 2011 Mar; 126(1-3):58-64. PubMed ID: 21095104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes.
    Youn S; Phillips LJ; Amminger GP; Berger G; Chen EYH; de Haan L; Hartmann JA; Hickie IB; Lavoie S; Markulev C; McGorry PD; Mossaheb N; Nieman DH; Nordentoft M; Riecher-Rössler A; Schäfer MR; Schlögelhofer M; Smesny S; Thompson A; Verma S; Yuen HP; Yung AR; Nelson B
    Schizophr Res; 2020 Feb; 216():255-261. PubMed ID: 31866077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.